Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Pediatric Plaque Psoriasis”

40 trials

Showing 20 of 40 results

Post-approval studies (Phase 4)Active Not RecruitingNCT03240809
What this trial is testing

An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects

Who this might be right for
Psoriasis
Bausch Health Americas, Inc. 2
Large-scale testing (Phase 3)Study completedNCT04435600
What this trial is testing

Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms

Who this might be right for
Psoriasis
AbbVie 139
Large-scale testing (Phase 3)Study completedNCT03701763
What this trial is testing

Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis

Who this might be right for
Psoriasis
Amgen 245
Large-scale testing (Phase 3)Study completedNCT02698475
What this trial is testing

An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than or Equal to 6 to Less Than 12 Years of Age

Who this might be right for
Psoriasis
Janssen Research & Development, LLC 44
Not applicableStudy completedNCT05388916
What this trial is testing

A Real-world Study to Assess Safety and Effectiveness of Secukinumab in Pediatric Plaque Psoriasis Patients in China

Who this might be right for
Moderate to Severe Chronic Plaque Psoriasis
Novartis Pharmaceuticals 42
Large-scale testing (Phase 3)Study completedNCT03668613
What this trial is testing

Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis

Who this might be right for
Moderate to Severe Chronic Plaque-type Psoriasis
Novartis Pharmaceuticals 84
Testing effectiveness (Phase 2)Study completedNCT04746911
What this trial is testing

Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216)

Who this might be right for
PsoriasisPlaque Psoriasis
Arcutis Biotherapeutics, Inc. 10
Large-scale testing (Phase 3)Study completedNCT04175613
What this trial is testing

A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis

Who this might be right for
Psoriasis
Amgen 160
Testing effectiveness (Phase 2)Study completedNCT02576678
What this trial is testing

Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis

Who this might be right for
Psoriasis
Amgen 42
Large-scale testing (Phase 3)Looking for participantsNCT03997786
What this trial is testing

Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis

Who this might be right for
Moderate-to-severe Chronic Plaque Psoriasis
Sun Pharmaceutical Industries Limited 130
Large-scale testing (Phase 3)Study completedNCT01251614
What this trial is testing

A Double Blind Study in Pediatric Subjects With Chronic Plaque Psoriasis, Studying Adalimumab vs. Methotrexate

Who this might be right for
Plaque Psoriasis
AbbVie (prior sponsor, Abbott) 114
Not applicableActive Not RecruitingNCT06142357
What this trial is testing

Secukinumab Drug Survival, Effectiveness and Tolerability in Pediatric Patients With Psoriasis

Who this might be right for
Moderate-to-severe Plaque Psoriasis
Novartis Pharmaceuticals 199
Large-scale testing (Phase 3)Study completedNCT00078819
What this trial is testing

Etanercept (Enbrel®) in Psoriasis - Pediatrics

Who this might be right for
Psoriasis
Amgen 211
Large-scale testing (Phase 3)Study completedNCT01090427
What this trial is testing

The Safety and Efficacy of Ustekinumab in Adolescent Patients With Psoriasis (CADMUS)

Who this might be right for
Psoriasis
Janssen Research & Development, LLC 110
Large-scale testing (Phase 3)Not Yet RecruitingNCT06833307
What this trial is testing

The Efficacy and Safety of SHR-1314 in the Treatment of Pediatric Patients of Age 6 to <18 Years With Moderate to Severe Plaque Psoriasis

Who this might be right for
Children and Adolescents Aged 6 to 18 With Moderate-to-Severe Plaque Psoriasis
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 90
Large-scale testing (Phase 3)Looking for participantsNCT04772079
What this trial is testing

Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Pediatric Participants With Moderate to Severe Plaque Psoriasis

Who this might be right for
Plaque Psoriasis
Bristol-Myers Squibb 153
Large-scale testing (Phase 3)Active Not RecruitingNCT05172726
What this trial is testing

Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects

Who this might be right for
Plaque Psoriasis
Organon and Co 58
Large-scale testing (Phase 3)Looking for participantsNCT06425549
What this trial is testing

Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis

Who this might be right for
Moderate to Severe Plaque Psoriasis
UCB Biopharma SRL 168
Testing effectiveness (Phase 2)Study completedNCT04655313
What this trial is testing

Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215)

Who this might be right for
PsoriasisPlaque Psoriasis
Arcutis Biotherapeutics, Inc. 20
Not applicableActive Not RecruitingNCT03218488
What this trial is testing

A Safety Study of Ustekinumab in the Treatment of Pediatric Participants Aged 6 Years and Older With Moderate to Severe Plaque Psoriasis

Who this might be right for
Psoriasis
Janssen-Cilag International NV 135
Load More Results

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation